Molecular basis of 60 years of antigenic evolution of human influenza A(H3N2) virus neuraminidase
Human influenza A viruses escape antibody-mediated immunity through changes in the hemagglutinin (HA) and neuraminidase (NA) glycoproteins.
Estimated impact of 2022–2023 influenza vaccines on annual hospital burden in the United States
Annual influenza epidemics in the United States cause hundreds of thousands of hospitalizations.
Global Respiratory Virus Activity by WHO
Global influenza and COVID-19 activity stayed low in late October 2025. COVID-19 was more common in northern regions, while influenza spread mainly in tropical areas.
News
Policy & Recommendations
Scientific Papers
Health preparedness: EU reference laboratories improve disease surveillance data
On the European Laboratory Day, held on 5 November, the European Commission marks one year of improved coordination on surveillance data thanks to the EU reference laboratories (EURLs).
Viral Infections and Risk of Cardiovascular Disease: Systematic Review and Meta‐Analysis
In self‐controlled case series studies, laboratory‐confirmed influenza infection was associated with an elevated risk of acute myocardial infarction and stroke during the first 1 month.
Influenza vaccine effectiveness and genetic diversity: insights from end-of-season community surveillance, France, 2024–2025
Influenza 2024–2025 season in France was characterized by prolonged duration, unusual co-circulation of all three viruses (A(H1N1)pdm09, A(H3N2), B/Victoria) with several subclades, and substantial healthcare impact.
News
Policy & Recommendations
The European Respiratory Virus Surveillance Summary (ERVISS)
Launched as an interactive dashboard, ERVISS offers weekly integrated data on influenza, RSV and SARS-CoV-2 across the EU/EEA and the WHO European Region.
High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults
High-dose inactivated influenza vaccine has been shown to provide protection against influenza that is superior to that with the standard dose.
